Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer

PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-Duarte, Raquel, Rebelo de Almeida, Cátia, Negrão, Magda, Fernandes, Afonso, Borralho, Paula, Sobral, Daniel, Gallego-Paez, Lina M., Machado, Daniel, Gramaça, João, Vílchez, José, Xavier, Ana T., Ferreira, Miguel Godinho, Miranda, Ana R., Mansinho, Helder, Brito, Maria J., Pacheco, Teresa R., Abreu, Catarina, Lucia-Costa, Ana, Mansinho, André, Fior, Rita, Costa, Luís, Martins, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365369/
https://www.ncbi.nlm.nih.gov/pubmed/34980600
http://dx.doi.org/10.1158/1078-0432.CCR-21-1992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365369/
https://www.ncbi.nlm.nih.gov/pubmed/34980600
http://dx.doi.org/10.1158/1078-0432.CCR-21-1992

Ejemplares similares